Pembrolizumab (MK-3475)

DRUG7 trials

Conditions

Bile Duct CancerBiliary Tract NeoplasmsBladder CancerCOVID-19CholangiocarcinomaColorectal CancerGallbladder CancerGastric Cancer

Phase 1

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

TerminatedNCT02346955

Famewave Ltd.Bladder Cancer, Colorectal Cancer, Gastric Cancer +3

Start: 2015-02-28End: 2017-02-28Updated: 2020-08-27

Pembrolizumab in Combination With CRT for LA-SCCHN

CompletedNCT02586207

Sanford HealthHead and Neck Cancer, Hypopharynx Cancer, Laryngeal Cancer +4

Start: 2015-11-30End: 2025-08-31Updated: 2025-10-07

Phase 2

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

CompletedNCT02736266

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoUrothelial Bladder Carcinoma

Start: 2017-02-27End: 2022-09-23Updated: 2023-07-18

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

CompletedNCT03111732

National Cancer Institute (NCI)Bile Duct Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma +2

Start: 2017-06-14End: 2021-11-08Updated: 2021-12-03

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Active, not recruitingNCT03504163

Memorial Sloan Kettering Cancer CenterBladder Cancer

Start: 2018-06-27End: 2026-04-30Updated: 2025-11-06

Checkpoint Blockade in COVID-19 Pandemic

TerminatedNCT04335305

MedSIRCOVID-19, Pneumonia, Viral

Start: 2020-04-09End: 2021-06-21Updated: 2022-06-21

Phase 3

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

CompletedNCT03783078

Merck Sharp & Dohme LLCMerkel Cell Carcinoma

Start: 2019-02-25End: 2024-02-15Updated: 2025-05-28

Future Oncology2025-06-121 citations

Muskelinvasives Harnblasenkarzinom: Ansprechen auf neoadjuvante Immuntherapie mit mpMRT mithilfe von VI-RADS-Scores beurteilen

Kompass Onkologie2025-06-06

Magnetic resonance imaging (MRI) radiomics as predictor of clinical outcomes to neoadjuvant immunotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy.

Journal of Clinical Oncology2025-05-28

Five-year median follow-up update of PURE-01: A phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology2025-05-28

Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.

2024-12-0110 citations

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.

2024-10-084 citations

MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL

The Journal of Urology2024-04-15

Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer

European Urology2024-01-0525 citations

Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer

British Journal of Urology2023-10-0718 citations

Performance of pre- and post-pembrolizumab vesical imaging–reporting and data system (VI-RADS) to predict the pathological response and efficacy outcomes in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from the PURE-01 trial.

JCO Global Oncology2023-08-01

Biology and performance of pre- and post-pembrolizumab (pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.

Journal of Clinical Oncology2023-06-01

Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).

Journal of Clinical Oncology2023-02-201 citations

Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VIRADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort.

Journal of Clinical Oncology2023-02-20

Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial

Clinical Cancer Research2022-10-0399 citations

An open-label, phase 2 study of personalized approach with perioperative immunotherapy for bladder preservation in muscle-invasive urothelial bladder carcinoma (MIBC).

Journal of Clinical Oncology2022-02-16

A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma

The Oncologist2022-01-0443 citations

PD42-05 FECAL MICROBIOTA PROFILING OF PATIENTS TREATED WITH NEOADJUVANT PEMBROLIZUMAB FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA

The Journal of Urology2021-08-04

Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.

Journal of Clinical Oncology2021-05-205 citations

Renal function outcomes in patients with muscle‐invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE‐01 study

International Journal of Cancer2021-03-158 citations

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology2021-02-2021 citations

31 more papers not shown

Pembrolizumab (MK-3475)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers